Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb receives EU approval for Opdivo in head and neck cancer

Bristol-Myers Squibb receives EU approval for Opdivo in head and neck cancer

2nd May 2017

Bristol-Myers Squibb has announced that its immuno-oncology therapy Opdivo has been granted a new approval by the European Commission.

The multipurpose drug has been approved as a monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.

It is the only immuno-oncology treatment that has demonstrated a significant improvement in overall survival for these patients in a phase III trial, with results from the global CheckMate-141 study helping to support this approval.

This means that Opdivo has now been approved by the European Commission for seven indications across five distinct tumour types.

Murdo Gordon, executive vice-president and chief commercial officer for Bristol-Myers Squibb, said: "Bristol-Myers Squibb remains committed to redefining survival for patients with cancer, and now that Opdivo is approved in Europe, we will work collaboratively with EU health authorities to ensure it is available for these patients as quickly as possible."

To date, the Opdivo clinical development programme has enrolled more than 25,000 patients.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801835365-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.